| Background: glioblastoma (Glioblastoma, GBM, WHO, IV) is the highestmalignant degree of glioma in adult astrocytic tumors, the annual incidence rate is3.19/100000, the disease mainly occurred in adult, with45~65years is most common inpatients and rarely under30years old. The male is more than female, male and femaleincidence ratio is3∶2. Currently, the preferred treatment of glioblastoma is operationtreatment, but because of its rich in blood vessels and diffuse infiltrative growth featuresmake tumors cannot be operated completely and recur easily. As a more effective andmost important mean of glioma, radiation therapy remains controversial because it isdifficult to repair the injury of central nervous system fully. Chemotherapy is anotheroption for treatment of glioma, but its side effects and drug resistance is still impassable.Although after operation, radiotherapy and chemotherapy, median survival ofglioblastoma is still relatively short, only3.3months (11.3~14.6months),5years ofrelative survival rate is only4.75%. With the development of molecular biology, tumorimmunology, biochemistry and biotechnology, glioma treatment is from the traditionaltreatment gradually into the molecular level named targeted therapy which put the cellreceptor, key genes and regulatory molecules as a target for treatment. So, targetsassociated with glioblastoma have extremely important social significance for clinicaltreatment of glioblastoma. The family of epidermal growth factor receptor (EGFR)consists of4members, named HER1(erbB1, EGFR), HER2(erbB2, NEU), HER3(erbB3) and HER4(erbB4). They are similar in structure, which is composed by threeparts: the ligand binding domain, single transmembrane region, highly conservedcytoplasmic protein tyrosine kinase region. Epidermal growth factor receptor bind itsligand in the extracellular domain and then interact to generate homodimer orheterodimer. The formation of dimer leads to activation of intracellular tyrosine kinase,and then phosphorylate the tyrosine residue of the receptor through phosphorylation andtransphosphorylation, start a series of signal transduction pathway in cytoplasm, send signal to the nucleus, activate a series of related gene, promote cells from G1phase to Sphase, and regulate growth, differentiation, proliferation, angiogenesis and apoptosis.The relationship between HER4and malignant tumors has become one of the researchfocuses to many scholars. Recent studies show that HER4-mediated signaling pathwayhas some connection with development and metastasis of many tumors. Already there isevidence that expression of HER4in a variety of malignant tumors was higher than thatin normal tissue, and its overexpression is often closely correlated with lymph nodemetastasis and distant metastasis. However, at home and abroad there have not yetfound specific description of HER4expression in glioblastoma.Objective: To study the expression of HER4in glioblastoma.Methods: Collect45cases of glioblastoma tumor tissue samples by operativeresection and experienced doctors diagnosed from2008to2011in Linyi People’sHospital. Another10cases of postoperative normal brain tissue samples(traumatic braininjury or cerebral hemorrhage cases)in the hospital for treatment were collected as acontrol. Expression of HER4was detected with immunohistochemical method inglioblastoma tumor and normal brain tissue.Results: HER4is mainly localized in the cytoplasm, HER4expressed in bothglioblastoma tumor tissue and normal brain tissue.HER4in normal brain tissue is notexcessively expressed but excessively expressed in glioblastoma tissues(P=0.037).Conclusion: HER4is an important regulatory gene for growth of glioblastoma,and human intervention in the over expression of HER4may be an effective method forthe treatment of glioblastoma. |
PDF Full Text Request